Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

By Michael Weller, N. Butowski, D. Tran, L. Recht, M. Lim, H. Hirte, L. Ashby, L. Mechtler, S. Goldlust, F. Iwamoto and 15 more. The Lancet Oncology, 2017

913 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/443ce2717d2152016dc723eaf7b74a6c575e5eaf